- Conditions
- Urothelial Carcinoma
- Interventions
- carboplatin, cisplatin, disitamab vedotin, gemcitabine, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 89
- States / cities
- Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
- Conditions
- Lower Extremity Amputation
- Interventions
- Caregiver socket, Prosthetist socket
- Device
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Colon Cancer, Metastatic Colon Cancer
- Interventions
- FOLFIRI regimen & bevacizumab, Fruquintinib, Lonsurf & bevacizumab, ST316
- Drug
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Advanced Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, Metastatic Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, NSCLC, Non-Small Cell Lung Cancer
- Interventions
- silevertinib (BDTX-1535) monotherapy
- Drug
- Lead sponsor
- Black Diamond Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Huntington Beach, California + 20 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- PF-06939926, Placebo
- Genetic · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2039
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 8 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Colorectal Neoplasms, Exocrine Pancreatic Cancer
- Interventions
- carboplatin, cisplatin, pembrolizumab, tisotumab vedotin
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 124
- States / cities
- Encinitas, California • La Jolla, California • Sacramento, California + 57 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- ABBV-CLS-7262, CNM-Au8, DNL343, NUZ-001, Pridopidine, SLS-005 Trehalose, Verdiperstat, Zilucoplan
- Drug
- Lead sponsor
- Merit E. Cudkowicz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
- Conditions
- Breast Cancer, Stage 0
- Interventions
- Breast MRI, Laboratory Biomarker Analysis
- Diagnostic Test · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 122 participants
- Timeline
- 2018 – 2032
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Serum Analytes
- Interventions
- Tasso+ Serum Gel Capillary Blood Collection System
- Diagnostic Test
- Lead sponsor
- Tasso Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Atlantis, Florida • Seattle, Washington
- Conditions
- Advanced Solid Tumor, Colorectal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
- Interventions
- 5Fluorouracil, Carboplatin, Cetuximab, Cisplatin, Gemcitabine, Irinotecan, LY4066434., Leucovorin, Nab paclitaxel, Oxaliplatin, Pembrolizumab, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 16 more
- Conditions
- Multiple Sclerosis
- Interventions
- Activated charcoal, Cholestyramine, Frexalimab, MRI contrast-enhancing agents, Placebo infusion, Placebo tablet, Teriflunomide
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 84 more
- Conditions
- Breast Cancer
- Interventions
- Avelumab, Trastuzumab, Utomilumab, Vinorelbine
- Drug
- Lead sponsor
- Adrienne G. Waks
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Colorectal Cancer
- Interventions
- Atezolizumab, Regorafenib, XL092
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 45
- States / cities
- Jonesboro, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
- Conditions
- Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis
- Interventions
- Pelabresib, Placebo, Ruxolitinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Imetelstat Sodium, Placebo
- Drug
- Lead sponsor
- Geron Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
- Conditions
- Gingival Inflammation and Bleeding, White Spot Lesions
- Interventions
- Placebo, Povidone-iodine solution
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
- Procedure · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
- Conditions
- Medulloblastoma
- Interventions
- Cisplatin, Cyclophosphamide, Laboratory Biomarker Analysis, Lomustine, Magnetic Resonance Imaging, Radiation Therapy, Vincristine, Vincristine Sulfate
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2028
- U.S. locations
- 173
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 134 more
- Conditions
- Lung Cancer
- Interventions
- lobectomy, segmentectomy or wedge resection
- Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2027
- U.S. locations
- 373
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 245 more
- Conditions
- Cardiac Catheterization, Coronary Computed Tomographic Angiography, Myocardial Infarction (MI)
- Interventions
- GSI Cardiac Scan, Research CCTA, Standard of Care CCTA
- Device · Other
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
- Interventions
- Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy
- Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2041
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more
- Conditions
- Atrophies, Facioscapulohumeral, Atrophy, Facioscapulohumeral, Dystrophies, Facioscapulohumeral Muscular, Dystrophies, Landouzy-Dejerine, Dystrophy, Facioscapulohumeral Muscular, Dystrophy, Landouzy-Dejerine, FMD, FMD2, FSH, FSH Muscular Dystrophy, FSHD, FSHD1, FSHD2, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Atrophy, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome, Muscular Dystrophies, Muscular Dystrophy, Facioscapulohumeral, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy
- Interventions
- AOC 1020
- Drug
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Eligibility
- 16 Years to 72 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 11 more
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- NXC-201 CAR-T
- Biological
- Lead sponsor
- Nexcella Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 18
- States / cities
- Berkeley, California • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
- Interventions
- ECMO support, PROSpect protocolized therapies
- Device · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 14 Days to 20 Years
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more